Fragile X Syndrome, Pipeline Review, H2 2019 - Healx Ltd, Novartis AG & Tetra Therapeutics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 9, 2020--
The “Fragile X Syndrome - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The Publisher’s Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Reasons to buy
Key Topics Covered:
Fragile X Syndrome - Overview
Fragile X Syndrome - Therapeutics Development
Fragile X Syndrome - Therapeutics Assessment
Fragile X Syndrome - Companies Involved in Therapeutics Development
Fragile X Syndrome - Drug Profiles
Fragile X Syndrome - Dormant Projects
Fragile X Syndrome - Discontinued Products
Fragile X Syndrome - Product Development Milestones
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/p4q3xz
View source version on businesswire.com:https://www.businesswire.com/news/home/20200109005359/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: PROFESSIONAL SERVICES CONSULTING
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 01/09/2020 05:51 AM/DISC: 01/09/2020 05:51 AM